Bifogade filer
Vimian has been approved for listing on Nasdaq Stockholm
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Nasdaq Stockholm’s Listing Committee has today approved Vimian Group AB (publ)’s (“Vimian” or the “Company”) application for admission of Vimian’s ordinary shares to trading on Nasdaq Stockholm. The approval is subject to customary conditions, including the approval and registration of a prospectus with the Swedish Financial Supervisory Authority. The first day of trading on Nasdaq Stockholm is expected to be Friday, 28 March 2025 and the last day of trading on Nasdaq First North Growth Market is expected to be Thursday, 27 March 2025.
Vimian’s ordinary shares will be traded in the Large Cap segment with unchanged ticker (VIMIAN) and unchanged ISIN code (SE0015961982). There will be no offer or issuance of new shares in connection with the change of marketplace to Nasdaq Stockholm and shareholders in Vimian do not need to take any action in connection therewith.
”For a global animal health company like Vimian, the change to Nasdaq Stockholm Main Market is an important milestone in the company’s development. It strengthens access to the Swedish and not least the international capital markets, and provides a quality stamp for shareholders and other stakeholders”, says Magnus Welander, Chairman of the Board of Directors in Vimian.
The shares in Vimian have been listed on Nasdaq First North Growth Market since 18 June 2021. The Board of Directors considers the listing of the Company’s ordinary shares on Nasdaq Stockholm to be a logical and important step in Vimian’s development. The uplisting is expected to lead to better liquidity in Vimian’s ordinary shares, a broader awareness of the Company and the right conditions to broaden the Company’s shareholder base.
”I am pleased to now take this important step as part of our journey towards our goal of tripling earnings and reaching an adjusted EBITA of over EUR 300 million by 2030. Vimian is well equipped for the future and ready to accelerate our growth journey in the global animal health market”, says Patrik Eriksson, CEO Vimian.
Advokatfirman Vinge is acting as legal advisor to Vimian in connection with the listing on Nasdaq Stockholm.